Abiopharma

Convening of a Annual General Assembly for the Company’s Shareholders on July 2, 2026.

Conflict Minerals Report for the reporting period January 1, 2025 to December 31, 2025

The company’s liability position as of 31.3.26, by maturity dates

Change in holdings of interested parties/officers

Q1 report for 2026

Net Asset Value(s)

Subject: Dividend Distribution Q1, 2026 - NIS 320,000,000

Infleqtion Expands UK Quantum Operations with New Oxford Innovation Centre and Manufacturing Hub

Navan Unlocks Savings for Travelers with First SAS NDC Direct Connect

Navan Strengthens European Train Offering with Swedish Rail Integration